Welcome to our dedicated page for Aim Immunotech news (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on Aim Immunotech stock.
AIM ImmunoTech Inc. (NYSE American: AIM) generates frequent news related to its development of immuno-pharma therapeutics, particularly its flagship product candidate Ampligen (rintatolimod). Company announcements emphasize research and development in cancers, viral diseases, immune-deficiency disorders, and cancers with unmet medical needs, as well as updates on its intellectual property portfolio and corporate actions.
News coverage for AIM ImmunoTech often focuses on clinical and scientific milestones. Recent communications describe progress in the DURIPANC clinical program, where Ampligen is evaluated in combination with AstraZeneca’s Imfinzi (durvalumab) for metastatic pancreatic cancer, and presentations of data from a completed Phase 2 study in advanced recurrent ovarian cancer combining Ampligen with cisplatin and Merck’s Keytruda (pembrolizumab). The company also highlights publications in peer-reviewed journals and abstracts accepted at major scientific meetings such as the Society for Immunotherapy of Cancer (SITC).
Another recurring theme in AIM’s news is the expansion of its intellectual property. The company has announced a European patent covering compositions of its proprietary dsRNAs, including Ampligen, for treating Long COVID, and a patent in Japan for using Ampligen with checkpoint inhibitors for cancer treatment. These updates are presented as part of AIM’s strategy to strengthen protection around Ampligen in oncology and post‑COVID indications.
Investors following AIM ImmunoTech’s news will also see items on financial and corporate developments, including stock dividends, participation in investor conferences, public offerings of common stock and warrants, and financing agreements such as a promissory note with an institutional investor. Regular news releases on quarterly financial results, capital-raising transactions, and shareholder meetings provide additional context on the company’s operations and governance.
This news page aggregates such announcements so readers can review AIM ImmunoTech’s clinical updates, patent developments, financing activities, and corporate communications in one place.
AIM ImmunoTech Inc. announced the completion of dosing for Cohort 3 in a Phase 1 clinical study investigating Ampligen as an intranasal therapy. The study, conducted by the Centre for Human Drug Research, involved 40 healthy subjects and reported no serious adverse events. Cohorts received escalating doses up to 500 μg, with Cohort 4 now receiving 1250 μg. The study aims to evaluate Ampligen’s safety and biological activity as a potential treatment for COVID-19 and other viral diseases. Future updates depend on ongoing trial results and regulatory approvals.
AIM ImmunoTech Inc. (NYSE American: AIM) reported its financial results for Q1 2021, highlighting a cash position of $63.6 million, up from $54.4 million at year-end 2020. Research and development expenses increased to $1.4 million from $0.9 million year-over-year, while general and administrative expenses decreased slightly to $2.1 million. The net loss improved to $3.6 million or $0.08 per share, compared to $3.8 million or $0.22 per share last year. CEO Thomas K. Equels emphasized advancements in clinical programs targeting cancer and viral diseases, including COVID-19.
AIM ImmunoTech Inc. (NYSE American: AIM) announced that CEO Thomas K. Equels participated in a 'Fireside Chat' video interview with Ed Woo from Ascendiant Capital Markets on May 3, 2021. The discussion highlighted AIM's recent accomplishments and key upcoming goals, as well as the financial and operational outlook for the company. AIM ImmunoTech focuses on developing therapeutics for multiple cancers, immune disorders, and viral diseases, including COVID-19. A link to the interview is available on AIM's website.
AIM ImmunoTech Inc. (NYSE American: AIM) announced the completion of dosing for Cohort 2 in its Phase 1 clinical study of Ampligen as an intranasal therapy. No serious adverse events were reported in either Cohort 1 or Cohort 2. The study aims to evaluate Ampligen's potential as a treatment for COVID-19 and other respiratory diseases. Following the current cohort, the next dose will escalate to 500 μg, with future plans for additional cohorts. AIM confirms it will provide updates on the study as it progresses.
AIM ImmunoTech Inc. (NYSE American: AIM) has successfully completed dosing for Cohort 1 in a Phase 1 clinical study of its intranasal drug Ampligen, with no serious adverse events reported. This study aims to assess Ampligen's safety and potential as a treatment for COVID-19 and other respiratory diseases. The trial, conducted by the Centre for Human Drug Research, includes 40 healthy subjects across 4 cohorts receiving varying doses of Ampligen. AIM is optimistic about moving to Phase 2 after these initial results, which may expedite the development of Ampligen for preventive treatment.
AIM ImmunoTech Inc. (NYSE American: AIM) reported its fiscal year 2020 results, showing a substantial cash increase to $54.4 million from $8.8 million in 2019. However, the net loss rose to $14.4 million, or $0.45 per share, compared to $9.4 million, or $2.58 per share, in the previous year. The company is advancing its research on Ampligen for COVID-19, with promising early results indicating a 90% reduction in viral yields. Clinical trials for cancer therapies are also ongoing, with notable positive survival data in pancreatic cancer patients.
AIM ImmunoTech Inc. (NYSE American: AIM) announced that Roswell Park Comprehensive Cancer Center has received Institutional Review Board approval for an amendment to its ongoing Phase 1/2a study. The amendment allows for the randomization of 20 additional patients assessing AIM's Ampligen combined with interferon alpha-2b for cancer patients with COVID-19. The trial's aim is to evaluate Ampligen's effectiveness as both a standalone therapy and in combination, with noted patient safety benefits.
AIM ImmunoTech Inc. (NYSE American: AIM) has announced that its CEO, Thomas K. Equels, will present at the Q1 Virtual Investor Summit from March 23-25, 2021. The presentation is scheduled for March 24 at 3:00 PM ET. This summit is an independent conference bringing together smallcap companies and investors. AIM ImmunoTech focuses on developing therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19. Interested parties can register for the event online.
AIM ImmunoTech Inc. (NYSE American: AIM) has announced that CEO Thomas K. Equels will present at the Inaugural Emerging Growth Virtual Conference, held from March 17-19, 2021. The conference features discussions with C-suite executives and presentations from numerous issuers in the healthcare sector. Attendees can access exclusive content by signing up as M-Vest members. AIM will also make its presentation available on its investor relations website. The company focuses on developing therapeutics for cancers, immune disorders, and viral diseases, including COVID-19.
AIM ImmunoTech has commenced its Phase 1 clinical trial to evaluate the safety of Ampligen as an intranasal therapy for COVID-19 and other respiratory viral diseases. Conducted by the Centre for Human Drug Research in the Netherlands, the study will involve 40 healthy subjects. Positive preliminary in vitro results indicate that Ampligen can decrease SARS-CoV-2 viral yields by 90%. CEO Thomas K. Equels expressed optimism about Ampligen's potential in preventing COVID-19 transmission.